Cellectar Biosciences Gains Momentum with Clinical Progress and Strategic Initiatives

Cellectar Biosciences is navigating a period of significant activity, marked by substantial advancements within its radiopharmaceutical pipeline and an enhanced profile across the scientific community.

On August 14, 2025, Cellectar released its second-quarter financial results for the year. As of June 30, 2025, the company?s cash position stood at approximately $11.0 million. This figure includes $2.3 million in net proceeds from warrant exercises completed in June. Furthermore, Cellectar bolstered its treasury through separate financing activities in June and July, raising nearly $9.5 million.

The reported net loss for Q2 2025 was $5.4 million. A notable reduction in research and development (R&D) expenditures was observed, which decreased to $2.4 million from $7.3 million in the comparable quarter of the previous year. This decline is primarily attributed to Read more...